Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom.
Adaptimmune Therapeutics stock last closed at $1.06, up 0% from the previous day, and has decreased 50.23% in one year. It has underperformed other stocks in the Biotechnology industry by 0.24 percentage points. Adaptimmune Therapeutics stock is currently +4.95% from its 52-week low of $1.01, and -60% from its 52-week high of $2.65.
As of Mar 29, 2023, there are 991.83M ADAP shares outstanding. The market capitalization of ADAP is $175.57M. In the last 24 hours, 355,219 ADAP shares were traded.
You need a brokerage account to access the NASDAQ market and buy ADAP stock.
Based on our research, eToro is the best brokerage. eToro gives you:
Get $10 towards your purchase of shares by opening an account with eToro today.
Open eToro AccountNow that you've picked the right brokerage, the next step is to fill out some personal information so you can invest in ADAP stock today.
Now that you've finished signing up on the best stock market app for beginners, you can securely and quickly fund your account:
Check out the walkthrough below to see the process of depositing funds into your new investment account.
After you have decided on the best place to buy Adaptimmune Therapeutics stock, it's crucial to analyze their stock prior to investing, so you truly comprehend the risk and upside.
WallStreetZen was designed to help everyday investors perform better fundamental analysis.
You can see all of the due diligence checks on ADAP's stock page.
Analysts use a variety of different financial metrics, analyses, models, and charts to gauge ADAP's true value.
Using relative valuations ratios:
You can do more valuation analysis on ADAP's stock here.
Out of 5 Wall Street analysts who give recommendations on ADAP, the consensus analyst rating on ADAP is a Buy
Please note that analyst forecasts are not recommendations, nor are they investment advice.
Tony Butler, a bottom 6% analyst from EF Hutton reiterates ADAP with a strong buy rating and maintains their ADAP price target from $10.00 to $10.00, on Mar 6, 2023.
Michael Schmidt, a top 15% analyst from Guggenheim upgrades ADAP to a strong buy rating and announces their ADAP price target of $5.00, on Jan 3, 2023.
Yanan Zhu, a bottom 2% analyst from Wells Fargo maintains ADAP with a hold rating and raises their ADAP price target from $1.50 to $3.00, on Nov 14, 2022.
Mara Goldstein, a bottom 38% analyst from Mizuho upgrades ADAP to a strong buy rating and announces their ADAP price target of $9.00, on Nov 9, 2022.
Nick Abbott, a bottom 24% analyst from Wells Fargo maintains ADAP with a hold rating and lowers their ADAP price target from $7.00 to $1.50, on Oct 4, 2022.
You can dig deeper into what analysts are forecasting on the Adaptimmune Therapeutics stock forecast page.
Last year, ADAP revenue was $27.15M. Over the last five year, ADAP's revenue has gone up by -6.42% per year. This was slower than the Biotechnology industry average of 41.18%.
Dive into ADAP's earnings and revenue performance here.
Over the past year, executives and large shareholders at ADAP have sold more shares than they have bought.
Cintia Piccina, Chief Commercial Officer of ADAP, was the latest ADAP insider to sell. They sold $22,234.30 worth of ADAP shares on Jan 31, 2023.
Dig into more about who owns ADAP shares here.
No, Adaptimmune Therapeutics doesn't provide an income stream by paying out dividends.
One of the primary reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to learn what other investors have to say.
You have two primary types of orders:
Click the Open button and eToro will execute the order.
If you need additional assistance investing in stocks on eToro, watch the helpful video below:
Now that you own some shares in ADAP, you'll want to stay up-to-date on your stock purchase.
Create a watchlist to keep tabs on your ADAP stock.
To summarize, here are the 6 steps you need to take to buy Adaptimmune Therapeutics stock right now:
If you are looking for a brokerage, eToro is our favorite option.
Get Started with eToro TodayIf you want to get notifications regarding your investment in Adaptimmune Therapeutics, click below.